deprescribing when less is more · ibuprofen (advil®), celecoxib (celebrex®) • some...
TRANSCRIPT
Deprescribing – when less is more
Barbara Farrell PharmD, FCSHP
May 2018
19 June 2018
Outline
• Why we use medications
• The risks of polypharmacy
• Tracking our medication use
• When to consider deprescribing
• Talking to your health care provider about polypharmacy and deprescribing
• Deprescribing at Bruyère Research Institute
• The Canadian Deprescribing Network
19 June 2018
Medications can:
• Treat symptoms
• Slow the progression of disease
• Reduce the risk of complications from disease
19 June 2018
Are seniors on too many meds?
2 out of 3 Canadians over the age of 65 take at least 5 different prescription medications
1 out of 4 Canadians over the age of 65 take at least 10 different prescription medications
Canadian Institute for Health Information. 2014. Drug Use Among Seniors on Public Drug Programs in Canada.
5
What’s it costing us?
• $419 million spent on potentially inappropriate medications (PIMs)
• $1.4 billion estimated for incremental health care expenditure due to PIMs
19 June 2018
Polypharmacy
19 June 2018
• Polypharmacy: more medications than needed, or for which harm outweighs benefit
• Increases risk of: – Adverse drug reactions, drug interactions
– Falls, fractures
– Functional and cognitive decline
– Nonadherence
– Hospitalizations and higher healthcare costs
• Especially for the elderly who handle and respond to drugs differently, are often frail and not represented in research
As we get older
• The brain becomes more sensitive to drug effects
• Some medications stay longer in our body because we have less muscle and more body fat
• Our liver and kidneys do not process medications as efficiently as when we were younger
• Our body contains less water and medications can become more concentrated
8
Which medications affect the bladder?
• Cholinesterase inhibitors: e.g. rivastigmine (Exelon®), donepezil (Aricept®)
• Opioids: e.g. codeine, morphine • Benzodiazepines: e.g. lorazepam (Ativan®) • Tricyclic antidepressants: e.g. amitriptyline (Elavil®) • Nasal decongestants • Antihistamines • Hormone replacement drugs: e.g. (Estrace®) • Antipsychotics: e.g. chlorpromazine (Largactil®) • Some diuretics: e.g. Furosemide (Lasix®) • Some non-steroidal anti-inflammatory drugs (NSAID): e.g.
ibuprofen (Advil®), celecoxib (Celebrex®) • Some antihypertensive drugs: e.g. nifedipine (Adalat®), amlodipine
(Norvasc®) • Some blood pressure medications: e.g. ACE inhibitors such as
enalapril (Vasotec®), ramipril (Altace®)
9
Which medications affect memory?
• Benzodiazepines/sedatives/sleeping pills: e.g.
alprazolam (Xanax®), zolpidem (Ambien®), lorazepam
(Ativan®)
• Antipsychotics: e.g. quetiapine (Seroquel®), risperidone
(Risperdal®), aripiprazole (Abilify®)
• First generation antihistamines: e.g. diphenhydramine
(Benadryl®), brompheniramine (Dimetapp®)
• Opioids: e.g. Oxycodone (OxyNeo®, Percocet®), Meperidine
(Demerol®), Codeine (Tylenol NO. 1®, NO. 2®, NO. 3®)
10
Which medications increase the risk of falls?
11
Sources: de Jong et al. 2013. Therapeutic Advances in Drug Safety.
4(4): 147-154 & Huang et al. 2012. Drugs & Aging 29(5):359-76
Risk of Drug-Drug interactions
Low risk
2 5-7 8-10
4-fold
greater risk
8-fold
greater risk
Number of medications
12
Johnell, K., Klarin, I. 2007.
Drug Safety; 30 (10): 911-
918
Medications may have unpredictable effects when they interact with each other. More medications means a higher chance of interactions.
How does polypharmacy happen?
• More medications than ever before
• People are living longer (and acquiring more diseases with more medications)
• Guidelines tell prescribers when to start drugs but not when to stop them
• Fear of ‘rocking the boat’
19 June 2018
Vintage ad for the benzodiazepine oxazepam (Serax®)
14
In the late 1970s, benzodiazepines are the most prescribed medication in the world. Women are generally more frequent consumers.
Benzodiazepines
• Diazepam, better known as Valium®, are approved for use (1963)
• Prescribed to relieve anxiety and facilitate sleep
• Even the occasional use can cause multiple harmful effects
15
What a drag it is getting old ‘Kids are different today’, I hear ev’ry mother say Mother needs something today to calm her down And though she’s not really ill There’s a little yellow pill She goes running for the shelter of a mother’s little helper - “Mother’s Little Helper” by The Rolling Stones, 1966
We all have a story: Johanna Trimble
Could this be you or a loved one?
• Side effects • Drug interactions • Prescribing cascades • Being ‘compliant’ • Falls • Hip fractures • Confusion • Emergency room
visits • Hospitalizations • Death
19 June 2018
Tracking your medication use
• Using the blank medication chart, fill in:
– The name of each of your medications
– Reason/goal
– When it was started and by who
– How to take it
– Intended duration (life-long? Or for certain timeframe?)
– Monitoring parameters
– Side effects to watch for
19 June 2018
Questions
• Put up your hand if you could fill in part of the chart
• Leave your hand up if you feel confident you could fill in every section of the chart
• What information was hard to recall?
• Why?
19 June 2018
What is deprescribing?
Deprescribing is the planned and supervised process of reducing or stopping medications that may no longer be of benefit or may be causing harm.
Deprescribing is part of good prescribing – backing off when doses are too high, or stopping medications that are no longer needed or might be causing harm.
20
19 June 2018
Steps in deprescribing
1. Compile a medication history
2. Identify potentially inappropriate medications, those with less evidence for benefit or those with harm
3. Assess each medication for eligibility for deprescribing
4. Prioritize medications for deprescribing
5. Develop a plan for tapering and monitoring
6. Monitor, support and document care
With the patient…
Deprescribing safely
• Monitor for adverse drug withdrawal events – Symptoms or signs caused by the removal of a drug:
1. Physiological - tachycardia (beta-blocker); rebound hyperacidity (PPI)
2. Symptoms of underlying condition - arthritis pain after stopping an NSAID
3. New symptoms - excessive sweating with stopping SSRI
– Increased risk with: • Longer duration, higher doses, short half-life • History of dependence/abuse • Lack of patient ‘buy-in’
19 June 2018
What can you do?
• Educate yourself about the medications you are taking and why
• Talk to your health care provider about deprescribing options and alternate therapies
• Spread the word about deprescribing to friends and family, advocacy groups and government representatives
• Be prepared and aware throughout your deprescribing plan
Ask questions, stay informed, be proactive, and participate in making smart choices!
24
19 June 2018
• Bruyère Deprescribing Guidelines Research Website: www.deprescribing.org • Canadian Deprescribing Network Website: www.deprescribingnetwork.ca • Choosing Wisely Canada Website: www.choosingwiselycanada.org • Institute of Safe Medication Practices Canada Website: www.ismp-canada.org
27
Organizations with resources that can help
Alternatives to sleeping pills/sedatives
Sleep hygiene, relaxation and cognitive behavioural therapy to achieve a regular and restorative sleep/wake cycle
28
Brochure available at:
www.deprescribingnetwork.ca/useful-resources
The work of the Bruyère Deprescribing Guidelines team
• Providing healthcare providers with evidence based guidelines and algorithms that help them help you decide when and how to reduce certain medications
• 5 algorithms available: Benzodiazepines, Antipsychotics, Proton Pump Inhibitors, Cholinesterase Inhibitors and Antihyperglycemics (www.deprescribing.org)
• Spreading the word: reaching out to community groups, engaging policy makers
• Networking with likeminded healthcare providers and organizations (locally and nationally)
19 June 2018
The Bruyère Deprescribing Research Program
Component Funder Timeline
Developing, implementing and evaluating evidence-based deprescribing guidelines
Government of Ontario (HSRF) and CIHR
2013-2016
Community pharmacists as catalysts for deprescribing
Canadian Foundation for Pharmacy
2016-2017
Spreading deprescribing knowledge, tools, resources and engaging stakeholders
Centre for Learning, Research and Innovation
2017-2019
Building capacity for deprescribing development, use and education
CC-ABHI – KMP2 2017-2018
A multi-method approach to exploring prescribing cascades
CIHR 2016-2020
Deprescribing Initiatives using community engagement
Government of Ontario (HSRF)
2017-2021
19 June 2018
Can someone add the front page of the PPI pamphlet here please? For some reason, we only have the back page (on next slide)
19 June 2018
Knowledge mobilization
• Website http://deprescribing.org
• Tools
• Publications
• Social media
• Symposium
• Presentations
• Networking
– CADTH, CIHI, Health Canada, MOHLTC, IHI etc
19 June 2018
Twitter (@deprescribing)
The Canadian Deprescribing Network
The Canadian Deprescribing Network is a group of health care leaders, clinicians, decision-makers, academic researchers and patient advocates working together to mobilize knowledge and promote the deprescribing of medication that may no longer be of benefit or that may be causing harm.
Governments
Research & innovation
Health
information
systems
Health-related
organizations
Health care
providers
Individual patients,
caregivers &
the public
Clinical decision
making
Health & social policies
Patient
empowerment
36
The Canadian Deprescribing Network
Goals:
• Raise awareness and decrease the inappropriate use of medications for seniors by 50% by 2020.
• Ensure access to safer drug and non-drug therapies.
37 37
Take home messages
• Polypharmacy in the elderly carries numerous risks
• Deprescribing is feasible and safe when supervised and monitored
• All deprescribing algorithms and ‘steps’ include: evaluating need for ongoing indication of each medication, weighing benefit and harm of continuing, developing and communicating a plan for deprescribing, carrying out deprescribing actions and monitoring
• It’s OK to talk to your prescriber about when deprescribing would be useful
• Remember to use non-drug approaches for symptom management when you can
19 June 2018
Bruyère Deprescribing Guidelines Research Team
Website: deprescribing.org
Email: [email protected]
Social: Twitter @deprescribing Facebook @deprescribing.org
Canadian Deprescribing Network
Website: deprescribingnetwork.ca
Email: [email protected]
Social: Twitter @DeprescribeNet Facebook @deprescribingnetwork
19 June 2018
Funding and Support
Deprescribing guidelines developed with funding from the Government of Ontario*, the Ontario Pharmacy Research Collaboration and Canadian Institutes of Health Research
*The views expressed in this presentation are the views of the author(s)/presenter(s) and do not necessarily reflect those of the Province.
